References
1. Cosnes, J., C. Gowerrousseau, P. Seksik et al., Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology,vol. 140,no. 6, pp. 1785-1794,2011.
2. Molodecky, N.A., I.S. Soon, D.M. Rabi et al., Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology,vol. 142,no. 1, pp. 46-54,2012.
3. Jiang, X.L. H.F. Cui, An analysis of 10218 ulcerative colitis cases in China. World Journal of Gastroenterology,vol. 8,no. 1, pp. 158-161,2002.
4. Zeng, Z., Z. Zhu, Y. Yang et al., Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: a prospective population-based study. Journal of Gastroenterology and Hepatology,vol. 28,no. 7, pp. 1148-1153,2013.
5. Walsh, A.J., R.V. Bryant S.P.L. Travis, Current best practice for disease activity assessment in IBD. Nature Reviews Gastroenterology & Hepatology,vol. 13,no. 567,2016.
6. Schroeder, K.W., W.J. Tremaine D.M. Ilstrup, Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New England Journal of Medicine,vol. 317,no. 26, pp. 1625-1629,1987.
7. Truelove, S.C. L.J. Witts, Cortisone in ulcerative colitis; final report on a therapeutic trial. British Medical Journal,vol. 2,no. 4947, pp. 1041-1048,1955.
8. Harbord, M., R. Eliakim, D. Bettenworth et al., Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. Journal of Crohn's & Colitis,vol. 11,no. 7, pp. 769-784,2017.
9. Ferrante, M., S. Declerck, G. De Hertogh et al., Outcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. Inflammatory Bowel Diseases,vol. 14,no. 1, pp. 20-28,2008.
10. Leijonmarck, C.E., P.G. Persson G. Hellers, Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study. Gut,vol. 31,no. 3, pp. 329-333,1990.
11. Ho, G.T., C. Mowat, C.J. Goddard et al., Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Alimentary Pharmacology and Therapeutics,vol. 19,no. 10, pp. 1079-1087,2004.
12. Hoie, O., F.L. Wolters, L. Riis et al., Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology,vol. 132,no. 2, pp. 507-515,2007.
13. Solberg, I.C., I. Lygren, J. Jahnsen et al., Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scandinavian Journal of Gastroenterology,vol. 44,no. 4, pp. 431-440,2009.
14. Ananthakrishnan, A.N., E.L. McGinley, D.G. Binion et al., Simple score to identify colectomy risk in ulcerative colitis hospitalizations. Inflammatory Bowel Diseases,vol. 16,no. 9, pp. 1532-1540,2010.
15. Dias, C.C., P.P. Rodrigues, A. da Costa-Pereira et al., Clinical predictors of colectomy in patients with ulcerative colitis: systematic review and meta-analysis of cohort studies. Journal of Crohn's & Colitis,vol. 9,no. 2, pp. 156-163,2015.
16. Ananthakrishnan, A.N., M. Issa, D.B. Beaulieu et al., History of medical hospitalization predicts future need for colectomy in patients with ulcerative colitis. Inflammatory Bowel Diseases,vol. 15,no. 2, pp. 176-181,2009.
17. Seo, M., M. Okada, T. Yao et al., Evaluation of the clinical course of acute attacks in patients with ulcerative colitis through the use of an activity index. Journal of Gastroenterology,vol. 37,no. 1, pp. 29-34,2002.
18. Peyrin-Biroulet, L., J. Panés, W.J. Sandborn et al., Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clinical Gastroenterology and Hepatology,vol. 14,no. 3, pp. 348-354,2016.
19. Koliani-Pace, J.L. C.A. Siegel, Beyond disease activity to overall disease severity in inflammatory bowel disease. The Lancet Gastroenterology and Hepatology,vol. 2,no. 9, pp. 624-626,2017.
20. Siegel, C.A., C.B. Whitman, B.M.R. Spiegel et al., Development of an index to define overall disease severity in IBD. Gut,vol. 67,no. 2, pp. 244-254,2018.
21. Magro, F., P. Gionchetti, R. Eliakim et al., Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. Journal of Crohn's & Colitis,vol. 11,no. 6, pp. 649-670,2017.
22. Seo, M., M. Okada, T. Yao et al., An index of disease activity in patients with ulcerative colitis. American Journal of Gastroenterology,vol. 87,no. 8, pp. 971-976,1992.
23. Frolkis, A.D., J. Dykeman, M.E. Negrón et al., Risk of Surgery for Inflammatory Bowel Diseases Has Decreased Over Time: A Systematic Review and Meta-analysis of Population-Based Studies. Gastroenterology,vol. 145,no. 5, pp. 996-1006,2013.
24. Macaluso, F.S., F. Cavallaro, C. Felice et al., Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review. Digestive and Liver Disease,vol.,2019.
25. D’Haens, G., W.J. Sandborn, B.G. Feagan et al., A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis. Gastroenterology,vol. 132,no. 2, pp. 763-786,2007.
26. Burisch, J., K.H. Katsanos, D.K. Christodoulou et al., Natural Disease Course of Ulcerative Colitis during the First Five Years of Follow-up in a European Population-based Inception Cohort - An Epi-IBD Study. Journal of Crohn's and Colitis,vol. 13,no. 2, pp. 198-208,2019.
1. Cosnes, J., C. Gowerrousseau, P. Seksik et al., Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology,vol. 140,no. 6, pp. 1785-1794,2011.